Previous validation has suggested that the risk score proformas outlined by HFA-ICOS underestimate the level of estimated cardiotoxic risk faced by HER2+ breast cancer patients who have received trastuzumab-based regimens [7]. Here, ERBB2 is linked to breast cancer.